Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a material event regarding its stock listing status on The Nasdaq Capital Market. The report date is May 30, 2023, with the filing signed on June 2, 2023.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock price thresholds.
Material Changes
On May 30, 2023, the Company received a notice from Nasdaq stating that its common stock closing bid price had been below the $1.00 minimum requirement for 30 consecutive trading days. This constitutes a failure to satisfy Nasdaq Listing Rule 5550(a)(2). The stock continues to trade under the symbol "BNGO" pending compliance.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has an initial 180 calendar days from the notice date to regain compliance.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days within the 180-day period.
- Extension Possibility: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and other initial listing standards.
- Delisting Risk: Failure to regain compliance within the applicable period(s) will result in the delisting of the Company's common stock.
- Management Action: Management intends to monitor the stock price and may consider implementing available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of BNGO stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading above $1.00 within the 180-day window.
- Check for any subsequent filings regarding a reverse stock split or other corporate actions intended to address the price deficiency.
- Review the Company's market value of publicly held shares to assess eligibility for a potential second compliance period.